1000878-09-0

Basic information

• Product Name: 5-(4-((1E, 6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1, 6-dien-1-yl)-2-methoxyphenoxy)-5-oxopentanoic acid
• Synonyms: 5-(4-((1E, 6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1, 6-dien-1-yl)-2-methoxyphenoxy)-5-oxopentanoic acid
• CAS NO: 1000878-09-0
• Molecular Weight: 482.487
• Mol File: 1000878-09-0.mol

Chemical Properties

• CAS DataBase Reference: 5-(4-((1E, 6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1, 6-dien-1-yl)-2-methoxyphenoxy)-5-oxopentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-((1E, 6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1, 6-dien-1-yl)-2-methoxyphenoxy)-5-oxopentanoic acid(1000878-09-0)
• EPA Substance Registry System: 5-(4-((1E, 6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1, 6-dien-1-yl)-2-methoxyphenoxy)-5-oxopentanoic acid(1000878-09-0)

Safety Data

• Hazardous Substances Data: 1000878-09-0(Hazardous Substances Data)

Upstream product

• 108-55-4 glutaric anhydride, 
• 458-37-7 curcumin 

Downstream Products

• 1330528-81-8 C₃₈H₄₄O₁₄ 

Relevant articles and documents

Cyclic peptide conjugate of curcumin and doxorubicin as an anticancer agent

The hydrophobicity of curcumin creates hurdle towards its use in the anticancer therapy. Herein, we synthesized a curcumin-doxorubicin conjugated cyclic peptide scaffold to improve the solubility of curcumin and create a conjugate containing two anticance

A supramolecular hydrogelator of curcumin

Here we report on the first supramolecular hydrogelator of curcumin and the evaluation of its inhibition capacity towards cancer cells and tumor growth.

Synthesis of novel Chlorin e6-curcumin conjugates as photosensitizers for photodynamic therapy against pancreatic carcinoma

Curcumin (cur) has been comprehensively studied for its various biological properties, more precisely for its antitumor potential and it has shown the promising results as well. On the other hand, Chlorin e6 (Ce6) has mostly been used as a photosensitizer in photodynamic therapy (PDT) against a variety of carcinomas. In the present study, we have synthesized a series of Chlorin e6-curcumin (Ce6-cur) conjugates and investigated their photosensitizing potential against pancreatic cancer cell lines. All the synthesized compounds were characterized by UV, 1H NMR, 13C NMR and LC-MS. These Ce6-cur conjugates showed better physicochemical properties and higher singlet oxygen generation capability. The cellular uptake was studied in AsPC-1 cells using fluorescence-activated cell sorting (FACS). Compound 17 was rapidly internalized within 30 min and sustained for 24 h. Compound 17 showed excellent PDT efficacy with IC50 of 40, 35 and 41 nM against AsPC-1, MIA PaCa-2 and PANC-1 respectively with exceptional dark/phototoxicity ratio in the range of 2371–7500. Moreover, the treatment of compound 17 upregulated the expression of BAX, Cytochrome-C and cleaved caspase 9 while downregulating the Bcl-2 expression an anti-apoptotic protein marker. These results demonstrate outstanding capability of compound 17 as a potent photosensitizer which could improve the PDT efficacy in pancreatic cancer patients.

A co-delivery system of curcumin and p53 for enhancing the sensitivity of drug-resistant ovarian cancer cells to cisplatin

In order to enhance the sensitivity of drug-resistant ovarian cancer cells to cisplatin (DDP), a co-delivery system was designed for simultaneous delivery of curcumin (CUR) and p53 DNA. Firstly, the bifunctional peptide K14 composed of tumor targeting pep

Release-Modulated Antioxidant Activity of a Composite Curcumin-Chitosan Polymer

Curcumin is known to have immense therapeutic potential but is hindered by poor solubility and rapid degradation in solution. To overcome these shortcomings, curcumin has been conjugated to chitosan through a pendant glutaric anhydride linker using amide

Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles

Inhibition of amyloid fibrillation and clearance of amyloid fibrils/plaques are essential for the prevention and treatment of various neurodegenerative disorders involving protein aggregation. Herein, we report curcumin- functionalized gold nanoparticles

An anti-DR5 antibody-curcumin conjugate for the enhanced clearance of activated hepatic stellate cells

Anti-death receptor 5 (DR5) antibody is a potential therapeutic agent for liver fibrosis because it exhibits anti-fibrotic effects by inducing the apoptosis of activated hepatic stellate cells (HSCs), which are responsible for hepatic fibrogenesis. Howeve

NOVEL CHLORIN E6-CURCUMIN DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR TREATMENT OF CANCER

The present invention relates to novel chlorine e6-curcumin derivatives, a preparation method thereof for the treatment of cancer, and in particularly, novel compounds were prepared by using different linkers such as hydrophobic and hydrophilic linkers to conjugate chlorine e6 to curcumin, the compounds under investigation showed excellent photophysical properties, stability, and anticancer activity.

Curcumin-antibody conjugates as anti-cancer agents

The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H3CO A represents —CH2—CH2— or —CH═CH—; L represents —C(O)—(NH)n1—R—(NH)n2—C(O)—; R represents a saturated or

CURCUMIN DERIVATIVES

The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.